Artelo Biosciences, Inc.
ARTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4 | $8 | $17 | $3 |
| - Cash | $2 | $2 | $1 | $2 |
| + Debt | $1 | $1 | $0 | $0 |
| Enterprise Value | $3 | $6 | $17 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3 | -$3 | -$2 | -$4 |
| % Margin | – | – | – | – |
| Net Income | -$3 | -$3 | -$2 | -$4 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.97 | -5.61 | -0.72 | -7 |
| % Growth | 29.2% | -679.2% | 89.7% | – |
| Operating Cash Flow | -$3 | -$1 | -$2 | -$3 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$1 | -$2 | -$3 |